Nuvation Bio Inc.
- NUVB
- NYSE
- Biotechnology
- Oncology Drug Development
- CDK Inhibitors
$4.45
Today −6.32%Quote Oct 16, 2026, 08:00 PM UTC
−26.69%over the last month
Max drawdown −27.0%From 1-month high −27.0%3 months −28.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$1.56B
Quote Oct 16
Next earnings
Nov 2
Expected, not confirmed
Analyst target
$20.50
+360.7% from here
Floor
$4.40
1.1% below price
Where the price sits
10 analysts
Analyst range, low to high
$20.00$21.00
- Price $4.45
- Resistance $4.58
- Consensus $20.50
The price is just above its floor and right under resistance. Analysts' average target sits about 361% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about NUVBPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $31.7M
- Product$23.2M73.2%
- License$8.5M26.8%
Industry
Biotechnology
Employees
305